[go: up one dir, main page]

PE20140675A1 - Comprimido farmaceutico de liberacion controlada para administracion oral - Google Patents

Comprimido farmaceutico de liberacion controlada para administracion oral

Info

Publication number
PE20140675A1
PE20140675A1 PE2013001406A PE2013001406A PE20140675A1 PE 20140675 A1 PE20140675 A1 PE 20140675A1 PE 2013001406 A PE2013001406 A PE 2013001406A PE 2013001406 A PE2013001406 A PE 2013001406A PE 20140675 A1 PE20140675 A1 PE 20140675A1
Authority
PE
Peru
Prior art keywords
polymer
oral administration
controlled release
release pharmaceutical
pharmaceutical tablet
Prior art date
Application number
PE2013001406A
Other languages
English (en)
Inventor
Arroyo Hector Senosiain
Paniagua Maria Angelica Arzola
Hernandez Gustavo Barranco
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140675(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of PE20140675A1 publication Critical patent/PE20140675A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPRIMIDO DE LIBERACION CONTROLADA NO HINCHABLE DE ADMINISTRACION ORAL CARACTERIZADO PORQUE EL PRINCIPIO ACTIVO SE ENCUENTRA EN UN SISTEMA MATRICIAL POLIMERICO EROSIONABLE Y DE LIBERACION POR DIFUSION FORMADO POR UN POLIMERO RETARDANTE Y UN POLIMERO FORMADOR DE MATRIZ, DONDE EL PRINCIPIO ACTIVO ES ENOXACINO, OFLOXACINO, CIPROFLOXACINO CLORHIDRATO, CIPROFLOXACINO BASE, LEVOFLOXACINO, ENTRE OTROS; EL POLIMERO RETARDANTE ES ETILCELULOSA, ACETATO DE CELULOSA, METILCELULOSA, ENTRE OTROS Y EL POLIMERO FORMADOR DE MATRIZ SE SELECCIONA DE HIDROXIPROPILMETILCELULOSA, HIDROXIETILCELULOSA, HIDROMETILCELULOSA Y METILCELULOSA
PE2013001406A 2010-12-17 2011-12-16 Comprimido farmaceutico de liberacion controlada para administracion oral PE20140675A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010014153A MX2010014153A (es) 2010-12-17 2010-12-17 Comprimido farmaceutico de liberacion controlada para administracion oral.

Publications (1)

Publication Number Publication Date
PE20140675A1 true PE20140675A1 (es) 2014-06-25

Family

ID=46245166

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001406A PE20140675A1 (es) 2010-12-17 2011-12-16 Comprimido farmaceutico de liberacion controlada para administracion oral

Country Status (11)

Country Link
BR (1) BR112013014963A2 (es)
CL (1) CL2013001707A1 (es)
CO (1) CO6721021A2 (es)
CR (1) CR20130288A (es)
DO (1) DOP2013000136A (es)
EC (1) ECSP13012766A (es)
GT (1) GT201300154A (es)
MX (1) MX2010014153A (es)
PE (1) PE20140675A1 (es)
RU (1) RU2603469C2 (es)
WO (1) WO2012080984A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016058813A1 (en) 2014-10-16 2016-04-21 Koninklijke Philips N.V. Aligning a patient within an mr scanner

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030133982A1 (en) * 2001-12-20 2003-07-17 Heimlich John M. Zero-order sustained release dosage forms and method of making same

Also Published As

Publication number Publication date
RU2603469C2 (ru) 2016-11-27
WO2012080984A3 (es) 2012-08-16
WO2012080984A2 (es) 2012-06-21
ECSP13012766A (es) 2013-09-30
CO6721021A2 (es) 2013-07-31
DOP2013000136A (es) 2013-10-15
BR112013014963A2 (pt) 2016-09-13
MX2010014153A (es) 2012-06-18
CL2013001707A1 (es) 2014-01-10
GT201300154A (es) 2014-05-07
RU2013127408A (ru) 2015-01-27
CR20130288A (es) 2013-08-13

Similar Documents

Publication Publication Date Title
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
EP4249055A3 (en) Tofacitinib oral sustained release dosage forms
EP2246052A4 (en) RASCH IN THE MOUTH DAMAGING TABLET WITH IMIDAFENACIN
DK2925272T3 (da) Lægemiddelopbevarings-, udleverings- og administrationssystem
NZ605352A (en) Process for producing glycosaminoglycans
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
LTPA2019508I1 (lt) Vaistų pristatymo sistema, skirta sunkiai vandenyje tirpstančių, farmaciškai aktyvių medžiagų, pateikimui
MX366230B (es) Composiciones multipolimericas para liberación transdermica de farmaco.
CY1118032T1 (el) Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
CL2013003161A1 (es) Composicion farmaceutica en forma de microgranulos de disolucion rapida para administracion vaginal que comprende a) un farmaco vaginalmente activo, b) un excipiente polimerico, c) un alcohol de azucar, sacarido o una mezcla de los mismos; procedimiento de preparacion.
MX2013001985A (es) Formulaciones a base de nalbufina y sus usos
JO3112B1 (ar) تركيبة دوائية سريعة التحلل
BR112013029199A2 (pt) sistema de distribuição de fármacos, dispositivo de distribuição de dois fármacos, método para preparar o mesmo, comprimido para administração sublingual de um ingrediente ativo, e, método para a administração de um ingrediente ativo a um indivíduo
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
CR20140358A (es) Sistema para la administración de fármacos
EA201291104A1 (ru) Пероральные лекарственные формы бендамустина
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
PE20140675A1 (es) Comprimido farmaceutico de liberacion controlada para administracion oral
CO6390098A2 (es) Formulaciones de desintegración rapida pre-compactadas de compuestos con baja biodisponibilidad oral.
UY35324A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
WO2013054178A8 (en) Extended release pharmaceutical compositions containing carmabazepine
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
EA201992463A1 (ru) Система доставки лекарственного средства
ES2422657A1 (es) Composición farmacéutica sólida de cilostazol

Legal Events

Date Code Title Description
FG Grant, registration